The different path of T790M-positive EGFR-mutant lung cancer

被引：2
作者：
Yoon, Shinkyo [1 ]
Choi, Chang Min [1 ,2 ]
Lee, Jae Cheol [1 ]
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, 88 Olymp Ro,43 Gil, Seoul 05505, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul, South Korea
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2018年 / 6卷
关键词：
RESISTANCE; OSIMERTINIB; MUTATION;
D O I：
10.21037/atm.2018.10.01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 12 条
  • [1] Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
    Chang, Yoon Soo
    Choi, Chang-Min
    Lee, Jae Cheol
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2016, 79 (04) : 248 - 256
  • [2] Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
    Chmielecki, Juliann
    Foo, Jasmine
    Oxnard, Geoffrey R.
    Hutchinson, Katherine
    Ohashi, Kadoaki
    Somwar, Romel
    Wang, Lu
    Amato, Katherine R.
    Arcila, Maria
    Sos, Martin L.
    Socci, Nicholas D.
    Viale, Agnes
    de Stanchina, Elisa
    Ginsberg, Michelle S.
    Thomas, Roman K.
    Kris, Mark G.
    Inoue, Akira
    Ladanyi, Marc
    Miller, Vincent A.
    Michor, Franziska
    Pao, William
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (90)
  • [3] Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
    Ercan, D.
    Zejnullahu, K.
    Yonesaka, K.
    Xiao, Y.
    Capelletti, M.
    Rogers, A.
    Lifshits, E.
    Brown, A.
    Lee, C.
    Christensen, J. G.
    Kwiatkowski, D. J.
    Engelman, J. A.
    Jaenne, P. A.
    [J]. ONCOGENE, 2010, 29 (16) : 2346 - 2356
  • [4] Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
    Gaut, Daria
    Sim, Myung Shin
    Yue, Yuguang
    Wolf, Brian R.
    Abarca, Phillip A.
    Carroll, James M.
    Goldman, Jonathan W.
    Garon, Edward B.
    [J]. CLINICAL LUNG CANCER, 2018, 19 (01) : E19 - E28
  • [5] Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    Lee, Jae Cheol
    Jang, Seung Hun
    Lee, Kye Young
    Kim, Young-Chul
    [J]. CANCER RESEARCH AND TREATMENT, 2013, 45 (02): : 79 - 85
  • [6] T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients
    Li, Wei
    Ren, Shengxiang
    Li, Jiayu
    Li, Aiwu
    Fan, Lihong
    Li, Xuefei
    Zhao, Cao
    He, Yayi
    Gao, Guanghui
    Chen, Xiaoxia
    Li, Shuai
    Shi, Jingyun
    Zhou, Caicun
    Fei, Ke
    Schmid-Bindert, Gerald
    [J]. LUNG CANCER, 2014, 84 (03) : 295 - 300
  • [7] Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
    Oxnard, Geoffrey R.
    Arcila, Maria E.
    Sima, Camelia S.
    Riely, Gregory J.
    Chmielecki, Juliann
    Kris, Mark G.
    Pao, William
    Ladanyi, Marc
    Miller, Vincent A.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1616 - 1622
  • [8] Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
    Park, Ji Hyun
    Choi, Yun Jung
    Kim, Seon Ye
    Lee, Jung-Eun
    Sung, Ki Jung
    Park, Sojung
    Kim, Woo Sung
    Song, Joon Seon
    Choi, Chang-Min
    Sung, Young Hoon
    Rho, Jin Kyung
    Lee, Jae Cheol
    [J]. ONCOTARGET, 2016, 7 (16) : 22005 - 22015
  • [9] Understanding and targeting resistance mechanisms in NSCLC
    Rotow, Julia
    Bivona, Trever G.
    [J]. NATURE REVIEWS CANCER, 2017, 17 (11) : 637 - 658
  • [10] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
12